CVRdatabase
Menu

Orbis Medicines ApS

Private limited companyCVR 42715646FrederiksbergActive

Orbis Medicines ApS is a private limited company, based in Frederiksberg, active in research and experimental development on natural sciences and engineering, founded in 2021. The company made a loss in both 2024 and 2025, most recently DKK 136.5m. With 32 employees, the company is about 6 times larger than the industry median. Equity grew to DKK 287.5m in 2025.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profit−DKK 114.1m−121% vs. 2024
Net profit−DKK 136.5m−268.8% vs. 2024
EquityDKK 287.5m+126.3% vs. 2024
Employees32latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss grew: from DKK 37m to DKK 136.5m (2024 → 2025).
  • Equity rose 126% (2024 → 2025), to DKK 287.5m.

Employees

  • 12 more employees than a year earlier: 32 (07/2026) against 20 (07/2025).

Management and owners, last 24 months

  • New in management: Alonso Ricardo Rodriguez (board member, 01/11/2024), Søren Møller (board member, 27/12/2024) and Morten Døssing (board member, 27/12/2024) (+5).
  • Stepped down: Søren Sylvester Skjærbæk (director, 01/02/2025), Morten Døssing (chair of the board, 26/12/2024) and Christian Heinis (board member, 27/12/2024) (+4).
  • New owners registered: Novo Holdings A/S (27/12/2024) and GF 2022 Global VC S.á r.l. (27/12/2024).
  • No longer registered as owner: Novo Holdings A/S (26/12/2024).

Registrations, last 24 months

  • 28/05/2026: Share capital changed from 2,849,471 DKK to 2,849,626 DKK
  • 02/10/2025: Share capital changed from 2,848,511 DKK to 2,849,471 DKK
  • 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
  • 27/12/2024: Share capital changed from 1,427,754 DKK to 2,848,511 DKK
  • 05/12/2024: Moved to Nordre Fasanvej 215, 2000 Frederiksberg

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2022–2025 · amounts in DKK thousand

Equity and net profit

−DKK 200m−DKK 100mDKK 0DKK 100mDKK 200mDKK 300m2022202320242025
EquityNet profit
Financial figures for Orbis Medicines ApS
2022202320242025Change
Revenuenot statednot statednot statednot stated–
Gross profit−15,220−25,596−51,629−114,118−121%
Operating profit (EBIT)−15,360−25,596−52,122−144,408−177.1%
Profit before tax−14,461−23,503−48,526−142,054−192.7%
Net profit−11,049−17,638−37,021−136,526−268.8%
Total assets28,71370,366158,639303,801+91.5%
Equity26,98768,950127,020287,463+126.3%
Liabilities1,7261,41631,62016,338−48.3%
Cash and cash equivalents19,01558,283128,867145,382+12.8%
Average number of employees00117+1,600%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 120m−DKK 100m−DKK 80m−DKK 60m−DKK 40m−DKK 20mDKK 02022202320242025
Gross profitMedian, the industry (431 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Loss for 4 years in a row

    Net result has been negative in 2022–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

4 financial years
Annual reports for Orbis Medicines ApS
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202523/06/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202428/05/2025The companyPDFXBRL
202301/01/2023 – 31/12/202318/04/2024The companyPDFXBRL
202228/09/2021 – 31/12/202229/06/2023The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
0510152025303511/2112/2101/2202/2203/2204/2205/2206/2207/2208/2209/2210/2211/2210/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

431 companies in the database

Comparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.

Gross profit−DKK 114.1mNo. 419 of 421
Better than 0% of the companies in the industry
EquityDKK 287.5mNo. 14 of 431
Better than 97% of the companies in the industry
Number of employees32No. 102 of 431
Better than 77% of the companies in the industry

Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.

DKK 100kDKK 2.5mDKK 63.4mDKK 1.6bnDKK 13.7bn
Distribution of gross profit for 250 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with 20–49 employees9,922 companies in the comparison
No. 9,887of 9,892
Better than 0%
No. 148of 9,922
Better than 99%
Same industry and 20–49 employees64 companies in the comparison
No. 60of 62
Better than 3%
No. 4of 64
Better than 95%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 33,582of 33,588
Better than 0%
No. 305of 33,687
Better than 99%
All companies of type ApS66,508 companies in the comparison
No. 66,376of 66,379
Better than 0%
No. 402of 66,505
Better than 99%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Research and experimental development on natural sciences and engineering
Gross profit
  1. Orbis Medicines ApS−DKK 114.1m
  2. Carlsberg A/SDKK 40.2bn
  3. Zealand Pharma A/SDKK 9.2bn
Net profit
  1. Orbis Medicines ApS−DKK 136.5m
  2. Carlsberg A/SDKK 7bn
  3. Zealand Pharma A/SDKK 6.5bn
Equity
  1. Orbis Medicines ApSDKK 287.5m
  2. Carlsberg A/SDKK 30.7bn
  3. Zealand Pharma A/SDKK 14.8bn
Employees
  1. Orbis Medicines ApS32
  2. Carlsberg A/S107
  3. Zealand Pharma A/S569

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
Orbis Medicines ApS

Management

7 active registrations

Executive management

Executive management at Orbis Medicines ApS
NameRoleAppointed
Morten DøssingCEO01/02/2025

Board of directors

Board of directors at Orbis Medicines ApS
NameRoleAppointed
Alonso Ricardo RodriguezBoard member01/11/2024
Søren MøllerBoard member27/12/2024
Morten DøssingBoard member27/12/2024
Edward Timothy MathersBoard member27/12/2024
Marco BoorsmaBoard member01/03/2025
Goran Mikael DolstenChair of the board01/03/2025
Founders
Novo Holdings A/S
Former management (8)
Former management at Orbis Medicines ApS
NameRoleAppointedResigned
Søren Sylvester SkjærbækDirector28/09/202101/02/2025
Morten DøssingChair of the board28/09/202126/12/2024
Christian HeinisBoard member28/09/202127/12/2024
João Carlos Ribas de AlmeidaBoard member28/09/202127/12/2024
João Carlos Ribas de AlmeidaDirector28/09/202123/10/2024
Vanessa CarleBoard member02/02/202427/12/2024
Marco BoorsmaBoard member02/02/202426/12/2024
Marco BoorsmaChair of the board27/12/202428/02/2025

Signing rule: Selskabet tegnes af en direktør i forening med formanden for bestyrelsen eller af den samlede bestyrelse.

Address and production units

1 active production units

Nordre Fasanvej 215
2000 Frederiksberg

Frederiksberg Municipality · Postcode 2000

Other companies at the address (8)

  • Sparrow Quantum ApSManufacture of computers and peripheral equipment
  • Adcendo ApSResearch and experimental development on natural sciences and engineering
  • Hemab ApSManufacture of pharmaceutical preparations
  • Minervax ApSResearch and experimental development on natural sciences and engineering
  • Inprother ApSResearch and experimental development on natural sciences and engineering
Production units
Production unitAddressEmployeesP number
Orbis Medicines ApSNordre Fasanvej 215, 2000 Frederiksberg331027580757

Purpose

Selskabets formål er forskning, udvikling og kommercialisering af medicinske produkter samt aktiviteter, der efter bestyrelsens skøn er forbundet dermed.

The purpose is quoted from the register in Danish.

Changes year by year

47 registered events
20262 changesaccounts 1 · capital 1
  • Annual report for 2025 published
  • Share capital changed from 2,849,471 DKK to 2,849,626 DKK
20258 changescapital 1 · accounts 1 · management 5 · industry 1
  • Share capital changed from 2,848,511 DKK to 2,849,471 DKK
  • Annual report for 2024 published
  • Goran Mikael Dolsten appointed chair of the board
  • Marco Boorsma appointed board member
  • Marco Boorsma stepped down as chair of the board
  • Morten Døssing appointed ceo
  • Søren Sylvester Skjærbæk stepped down as director
  • Industry changed to Research and experimental development on natural sciences and engineering (721000)
202423 changescapital 2 · management 13 · ownership 6 · address 1 · accounts 1
  • Share capital changed from 1,427,754 DKK to 2,848,511 DKK
  • Marco Boorsma appointed chair of the board
  • Søren Møller appointed board member
  • Morten Døssing appointed board member
  • Edward Timothy Mathers appointed board member
  • Vanessa Carle stepped down as board member
  • João Carlos Ribas de Almeida stepped down as board member
  • Christian Heinis stepped down as board member
  • Novo Holdings A/S registered as owner (33.33%)
  • GF 2022 Global VC S.á r.l. registered as owner (10%)
  • Marco Boorsma stepped down as board member
  • Morten Døssing stepped down as chair of the board
  • Novo Holdings A/S is no longer registered as owner
  • Moved to Nordre Fasanvej 215, 2000 Frederiksberg
  • Alonso Ricardo Rodriguez appointed board member
  • João Carlos Ribas de Almeida stepped down as director
  • Annual report for 2023 published
  • Share capital changed from 850,660 DKK to 1,427,754 DKK
  • Vanessa Carle appointed board member
  • Marco Boorsma appointed board member
  • Novo Holdings A/S registered as owner (50%)
  • Forbion Ventures Fund VI Coöperatief U.A. registered as owner (33.33%)
  • Novo Holdings A/S is no longer registered as owner
20233 changescapital 1 · ownership 1 · accounts 1
  • Share capital changed from 354,209 DKK to 850,660 DKK
  • Christian Heinis is no longer registered as owner
  • Annual report for 2022 published
20221 changecapital 1
  • Share capital changed from 182,572 DKK to 354,209 DKK
202110 changesownership 4 · founded 1 · management 5
  • Novo Holdings A/S registered as owner (90%)
  • Christian Heinis registered as owner (5%)
  • Novo Holdings A/S is no longer registered as owner
  • Registered as Orbis Medicines ApS
  • Søren Sylvester Skjærbæk appointed director
  • João Carlos Ribas de Almeida appointed director
  • Morten Døssing appointed chair of the board
  • João Carlos Ribas de Almeida appointed board member
  • Christian Heinis appointed board member
  • Novo Holdings A/S registered as owner (100%)

Related companies

Same industry in Frederiksberg

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction